{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:08:16Z","timestamp":1789178896462,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.jp","jtcvsopen.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTCVS Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xjon.2026.101684","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:41:59Z","timestamp":1771375319000},"page":"101684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical effect of proprotein convertase subtilisin\/kexin type 9 inhibition in patients undergoing coronary artery bypass surgery"],"prefix":"10.1016","volume":"30","author":[{"given":"Giuseppe","family":"Nasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Santarpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Vignaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Taverna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Larosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bartolomucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Siro","family":"Brigiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Contegiacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Speziale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.xjon.2026.101684_bib1","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"Giugliano","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.xjon.2026.101684_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.xjon.2026.101684_bib3","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.xjon.2026.101684_bib4","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1056\/NEJMc0707445","article-title":"A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N Engl J Med"},{"issue":"39","key":"10.1016\/j.xjon.2026.101684_bib5","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.xjon.2026.101684_bib6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.xjon.2026.101684_bib7","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.xjon.2026.101684_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.xjon.2026.101684_bib9","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology solution set oversight committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.xjon.2026.101684_bib10","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae170","article-title":"Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry","volume":"31","author":"Gargiulo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.xjon.2026.101684_bib11","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/jcm13030907","article-title":"Safety and efficacy of PCSK9 inhibitors in patients with acute coronary syndrome who underwent coronary artery bypass grafts: a comparative retrospective analysis","volume":"13","author":"Nasso","year":"2024","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.xjon.2026.101684_bib12","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.jtcvs.2016.01.050","article-title":"Outcomes in patients undergoing coronary artery bypass graft surgery in the United States based on hospital volume, 2007 to 2011","volume":"151","author":"Kim","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"10.1016\/j.xjon.2026.101684_bib13","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.athoracsur.2013.05.050","article-title":"A contemporary cost analysis of postoperative morbidity after coronary artery bypass grafting with and without concomitant aortic valve replacement to improve patient quality and cost-effective care","volume":"96","author":"Lapar","year":"2013","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"10.1016\/j.xjon.2026.101684_bib14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-0029-1185915","article-title":"Cardiac surgery in Germany during 2008. a report on behalf of the German Society for Thoracic and Cardiovascular Surgery","volume":"57","author":"Gummert","year":"2009","journal-title":"Thorac Cardiovasc Surg"},{"issue":"10","key":"10.1016\/j.xjon.2026.101684_bib15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa0804626","article-title":"Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease","volume":"360","author":"Serruys","year":"2009","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.xjon.2026.101684_bib16","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.xjon.2026.101684_bib17","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13063-022-06398-3","article-title":"Evolocumab administration prior to coronary artery bypass grafting in patients with multivessel coronary artery disease (EVOCABG): study protocol for a randomized controlled clinical trial","volume":"23","author":"Na","year":"2022","journal-title":"Trials"},{"issue":"10509","key":"10.1016\/j.xjon.2026.101684_bib18","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(25)01633-2","article-title":"Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial","volume":"406","author":"Verma","year":"2025","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.xjon.2026.101684_bib19","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.3390\/jcm13102987","article-title":"Evolocumab treatment in dyslipidemic patients undergoing coronary artery bypass grafting: one-year safety and efficacy results","volume":"13","author":"Nasso","year":"2024","journal-title":"J Clin Med"},{"issue":"10059","key":"10.1016\/j.xjon.2026.101684_bib20","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.xjon.2026.101684_bib21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.xjon.2026.101684_bib22","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.xjon.2026.101684_bib23","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM199010043231404","article-title":"Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. report of the program on the surgical control of the hyperlipidemias (POSCH)","volume":"323","author":"Buchwald","year":"1990","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.xjon.2026.101684_bib24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.xjon.2026.101684_bib25","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.xjon.2026.101684_bib26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xjon.2026.101684_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/aca.ACA_133_18","article-title":"Statin reload before off-pump coronary artery bypass graft: effect on biomarker release kinetics","volume":"23","author":"Kaushik","year":"2020","journal-title":"Ann Card Anaesth"},{"issue":"9965","key":"10.1016\/j.xjon.2026.101684_bib28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.xjon.2026.101684_bib29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.xjon.2026.101684_bib30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jacc.2020.11.011","article-title":"Effect of evolocumab on complex coronary disease requiring revascularization","volume":"77","author":"Oyama","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.xjon.2026.101684_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.121.011382","article-title":"Effect of evolocumab in patients with prior percutaneous coronary intervention","volume":"15","author":"Furtado","year":"2022","journal-title":"Circ Cardiovasc Interv"}],"container-title":["JTCVS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666273626001075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666273626001075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:32:44Z","timestamp":1789176764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666273626001075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"alternative-id":["S2666273626001075"],"URL":"https:\/\/doi.org\/10.1016\/j.xjon.2026.101684","relation":{},"ISSN":["2666-2736"],"issn-type":[{"value":"2666-2736","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical effect of proprotein convertase subtilisin\/kexin type 9 inhibition in patients undergoing coronary artery bypass surgery","name":"articletitle","label":"Article Title"},{"value":"JTCVS Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjon.2026.101684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery.","name":"copyright","label":"Copyright"}],"article-number":"101684"}}